Singapore: China's Luqa Pharmaceuticals has completed a $15 million round of fund raising, led by Morningside Ventures.

Luqa launched its first product in 2013 and additional eight products, with three more launches expected in 2015 in derma-aesthetic space.

According to Mr Robert Braithwaite, CEO, Luqa "The financing provides capital necessary to substantially grow, providing unique physician driven solutions for Chinese patients. We continue to strive to build a modern healthcare model, well adapted to today's China needs, based on strengthening the relationship between patients and providers through education and information."